United States Patent 8,334,270 (US8334270) Scope, Claims, and US Patent Landscape: what compounds, formulations, and methods are covered
US 8,334,270 is a US patent with a claim set that is dominated by a stereochemically defined, substituted phosphoramidate/phosphorylamino prodrug scaffold bearing a fluorinated, oxygenated ribose-like bicyclic fragment and a substituted phenoxy group tethered through a phosphorus center. The independent claim strategy is compound-centric, then broadens into (i) tighter stereochemical subsets, (ii) pharmaceutical compositions, and (iii) treatment methods for multiple viruses with explicit coverage for hepatitis C virus (HCV), plus combination therapy.
The operative implication for freedom-to-operate and challenge design is that infringement turns on matching the claim’s full structural requirements, especially stereochemistry at the defined centers, the specific “dioxo-dihydropyrimidinyl” unit, the fluorinated tetrahydrofuran fragment, and the particular phenoxy substitution pattern (phenoxy vs 4-fluorophenoxy vs 4-chlorophenoxy). The dependent claims then narrow by selecting fewer enumerated species from the independent claim’s list.
What compounds are claimed in US Patent 8,334,270 and how broad is the chemical coverage?
Direct answer: The patent claims a set of enumerated stereoisomeric prodrug compounds selected from a small number of phenoxy variants (phenoxy, 4-fluorophenoxy, 4-chlorophenoxy) combined with defined stereochemical variants at two stereocenters and a defined fluorinated tetrahydrofuran-like core, with N-linked amino acid ester variations including methyl, isopropyl, and cyclohexyl ester forms.
What is the core structure (the “must-have” elements)?
Across claim 1 and the dependent claim chain, the claim language repeatedly requires:
- A phosphoryl-amino (phosphorylamino) linkage: “...phosphoryl)amino...”
- A fluorinated tetrahydrofuran fragment: “...4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl...”
- An attached substituted dihydropyrimidine with two carbonyls: “...2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl...”
- A methoxy-methylene ether to the phenoxy group: “...methoxy)(phenoxy)phosphoryl...”
- A stereochemically constrained scaffold denoted by explicit “(2R,3R,4R,5R)” on the core ring fragment.
- Overall S-configuration selection for the final amino acid/prochiral center:
- The claim repeatedly uses “(S)-methyl ...”, “(S)-isopropyl ...”, “(S)-cyclohexyl ...”
- and then includes “(S)” and “(R)” choices at an additional stereocenter inside the phosphoramidate amino substituent: “(S)-(((...))methoxy)(phenoxy)phosphoryl)amino)propanoate” and “(R)-(((...))... )amino)propanoate”.
How many compound “families” are enumerated in claim 1?
Claim 1 enumerates species by combining:
- Ester alcohol identity (end-group):
- methyl (methyl ester)
- isopropyl (isopropyl ester)
- cyclohexyl (cyclohexyl ester)
- Stereochemistry at the amino acid/prochiral center:
- includes both “(S)-…propanoate” and “(R)-…propanoate” in the enumerations
- Phenoxy substitution pattern at phosphorus:
- “(phenoxy)” (unsubstituted phenoxy)
- “(4-fluorophenoxy)”
- “(4-chlorophenoxy)”
Net effect: claim 1 covers multiple enumerated prodrug species that differ by (i) ester alcohol, (ii) stereochemistry at the “propanoate” substituent, and (iii) phenoxy substitution.
What does claim 1 exclude?
Claim 1’s enumerated list is not “Markush-wide” across all phenoxy substituents or across all ester types. It is limited to the named alcohols and phenoxy patterns appearing in the claim. The long “claim 16” list that follows suggests the patent family broader scope exists in later claim sets, but claim 1 itself is narrower than the later enumerations.
Which dependent claims narrow claim 1 to specific stereoisomer subsets?
Direct answer: Dependent claims 2-9 pick out subsets that keep the same scaffold but reduce the enumerated combinations of ester alcohol and phenoxy type, often collapsing to one alcohol identity and one phenoxy substitution while still allowing (S)/(R) stereochemical variants where listed.
Dependent claim map (compound selection narrowing)
- Claim 2: limits claim 1 to methyl (S) configurations and only the listed phenoxy variant (phenoxy only) in the enumerated subset shown (it includes methyl with the (S)- and (R)-phosphoramidate stereochemical variants).
- Claim 3: selects a single compound from claim 1 enumerations:
- (S)-isopropyl ester with the specified “(R)” phosphoramidate stereochemical variant.
- Claim 4: selects methyl compounds for both (S) and (R) internal stereochemical variants (still within the methyl phenoxy set).
- Claims 5 and 6: select only one of the methyl species variants from claim 4 (one for “(S)” and one for “(R)” internal stereochemistry).
- Claims 7-9: narrow to cyclohexyl ester compounds and specifically the 4-fluorophenoxy variant, again with (S)/(R) internal stereochemical options in the enumerations.
This pattern makes the claim set commercially relevant: any generic developer attempting “design around” by altering the ester alcohol or the phenoxy substitution can reduce exposure to the narrower dependent-claim slices, but still may run into the independent-claim enumerated set if the exact species is within claim 1.
What formulations are covered: pharmaceutical composition claims 10–12?
Direct answer: The patent claims pharmaceutical compositions containing “the compound according to claim 1” and then requires an effective amount for HCV treatment.
- Claim 10: pharmaceutical composition comprising the compound of claim 1
- Claim 11: adds “pharmaceutically acceptable medium”
- Claim 12: effective amount to treat hepatitis C virus infection
Practical scope: this is standard US-style composition coverage. The legal question for a formulation challenge is whether the product’s active ingredient is one of the claimed enumerated species of claim 1 (or one of the selected species under dependent claims).
What treatment methods are claimed (HCV and other viruses), and is combination therapy covered?
Direct answer: Method claims are directed to administering an effective amount of the claimed compound to treat multiple viruses, with an explicit HCV claim subset and explicit coverage for adding another antiviral agent.
Method-of-use claim structure
- Claim 13: administer effective amount to treat a virus selected from:
- hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus, Japanese encephalitis virus
- Claim 14: narrows to hepatitis C virus
- Claim 15: for claim 14, further comprises administering an effective amount of another antiviral agent
Implication for generics and challengers: Even if a third party markets for non-HCV indications, the method claims that include HCV create exposure where label or physician practice aligns with those covered treatment patterns. For litigation posture, combination regimens matter because claim 15 recites add-on administration of another antiviral agent alongside the claimed compound.
What is the larger compound universe in claim 16 onward (and why does it matter)?
Direct answer: Claims 16-19 and the associated composition and method claims pivot to a much larger enumerated list of stereochemically specified prodrugs. Claim 16 is the key expansion point because it introduces many additional ester variations and phenoxy substitution patterns, plus other substituent variations including halogenated phenoxy groups and naphthoxy.
Claim 16: enumerated prodrug list expansion
Claim 16 recites “A compound or its stereoisomer thereof selected from among …” followed by a large set of individual compound names. The list includes, among others:
- Phenoxy framework with stereochemical core: “...phenoxy-phosphorylamino...”
- 4-bromo-phenoxy variants
- 2,4-dichloro-phenoxy variants
- 3,4-dichloro-phenoxy variants
- 2-chloro-phenoxy variants
- naphthalen-1-yloxy variants
- p-tolyloxy variants
- additional ester alcohol variations beyond claim 1:
- ethyl, butyl, sec-butyl, cyclohexyl, benzyl, isopropyl, pentyl, cyclopentyl, cyclopropyl methyl ester, etc.
It also includes acetic acid methyl ester and other chain-length modifications (propionic acid methyl ester vs butyric acid methyl ester vs acetic acid methyl ester), plus additional side chain substituent types such as 3-methyl-butyric acid methyl ester, 2,2-difluoroethyl ester, and multiple fluorinated ester motifs.
Claim 17-19: further narrowing and inclusion of additional stereochemical variants
- Claim 17: depends on claim 16 and selects among many of those enumerated species (a subset drawn from the claim 16 universe).
- Claim 18 and Claim 19: again depend on the prior claim and further narrow to smaller enumerated sets for both methyl and non-methyl ester types and include cyclohexyl and naphthyl/fluorophenoxy combinations.
Commercial relevance: claim 1’s independent claim is a limited subset, but claim 16 creates a broader infringement hook against products that fall into that expanded enumerated list. For design-around, a developer must avoid not only the phenoxy substitution variants but also the specific ester chain lengths and stereochemical configurations named.
What are the composition and method claims tied to claim 16 (20–25)?
Direct answer: Claims 20-22 repeat composition and HCV-treatment coverage for “the compound according to claim 16,” and claims 23-25 repeat multi-virus and HCV method coverage for the claim 16 compound universe, again including add-on combination therapy.
- Claim 20: pharmaceutical composition comprising the compound according to claim 16
- Claim 21: adds pharmaceutically acceptable medium
- Claim 22: effective amount to treat HCV infection
- Claim 23: administer to treat a virus selected from the same multi-virus list as claim 13 (including HCV)
- Claim 24: virus is HCV
- Claim 25: for claim 24, further comprises administering another antiviral agent
Net effect: the patent has two parallel tracks: claim 1-based coverage and claim 16-based coverage, each with composition and method-of-use claims that include HCV and combination therapy.
Where does infringement risk concentrate: which claim elements are most “design-around resistant”?
Direct answer: The most design-around resistant elements are the combination of:
- the fluorinated tetrahydrofuran fragment with the specified stereochemistry (2R,3R,4R,5R),
- the “2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl” unit,
- the phosphoryl-amino connection,
- the phenoxy/named aryloxy group,
- and the specific stereochemical selections (S/R) and named ester groups.
Changing only one parameter (for example, switching methyl ester to ethyl ester) may avoid claim 1 species but still trigger claim 16 enumerated coverage if the new ester and phenoxy pattern appear in that long list.
How does claim scope compare to “Markush” breadth: is this patent likely to be easy or hard to design around?
Direct answer: US 8,334,270 is hard to design around if the target product is intended to stay within the same prodrug class, because both independent claim 1 and independent claim 16 are implemented as lists of explicit chemical species rather than a broad generic Markush over “any alkyl ester” or “any halo-substituted phenoxy.”
That structure increases litigation precision: infringement analysis can be done by direct comparison of the marketed active ingredient’s exact structure against the claim’s enumerated species list.
US patent landscape: what other patents typically surround this scaffold (and how US 8,334,270 fits)
Because the question asks for “detailed analysis of the scope and claims and patent landscape” for US 8,334,270, the landscape view should reflect that this patent is scaffold-level prodrug chemistry with:
- stereochemical enumerations,
- phenoxy aryloxy variants,
- ester/side-chain ester variants,
- and downstream use in antiviral treatment, including HCV and combination therapy.
In practice, patents around such a scaffold usually split into:
- core compound/prodrug claims (like this patent’s claim 1 and 16),
- intermediate synthesis and process claims (manufacturing/IP barriers),
- formulation claims (dosage form, excipients, stability),
- salt/isomer claims (if salts are used in product),
- combination regimen claims (specific co-administered antivirals),
- and polymorph/hydrate patents if solid-state forms are critical.
However, no bibliographic data (assignee, priority date, related family members, continuation chain, or corresponding EP/WO numbers) are provided in the prompt, so a complete cross-reference landscape cannot be computed here without external patent-record retrieval. The scope analysis above is therefore limited to what is inferable from the provided claims.
Key takeaways
- US 8,334,270 is compound-list driven: it claims enumerated, stereochemically defined prodrug species, not a broad generic Markush across all esters or aryl oxy groups.
- Claim 1 covers a limited set of ester alcohols (methyl, isopropyl, cyclohexyl) with phenoxy variants including phenoxy, 4-fluorophenoxy, and 4-chlorophenoxy.
- Claim 16 expands to a much larger enumerated universe of prodrug species, adding many additional ester types (including ethyl, butyl, sec-butyl, benzyl, cycloalkyl esters) and additional aryloxy variants (including 4-bromo-phenoxy, dichloro-phenoxy, naphthalen-1-yloxy, and p-tolyloxy), with “compound or its stereoisomer thereof” language.
- The patent includes both composition claims and method-of-use claims for multiple viruses, with explicit HCV coverage and explicit add-on combination therapy coverage.
- From a design-around perspective, exposure concentrates on whether the marketed active ingredient matches any enumerated species in claim 1 or claim 16, with stereochemistry, aryl oxy substitution, and ester identity as the core infringement determiners.
FAQs
1) Do claim 10–12 require the same compound as claim 1, or can other claim sets satisfy composition infringement?
They require the compound according to claim 1, because the composition claims are explicitly tied to claim 1 (and a parallel set exists tied to claim 16 via claims 20–22).
2) Is combination therapy with another antiviral explicitly covered for HCV?
Yes. Claim 15 covers HCV treatment with the additional administration of another antiviral agent; the parallel combination coverage appears in claim 25 for the claim 16 track.
3) Can changing from a methyl ester to an ethyl ester avoid all infringement?
It can avoid the specific claim 1 enumerated methyl species, but not necessarily claim 16 coverage, because claim 16 enumerates multiple ester identities including ethyl esters for species that retain the same scaffold features.
4) Are non-HCV viral indications covered only in broad “any virus” language or with explicit listing?
They are explicitly listed in the method claims: West Nile, yellow fever, dengue, rhinovirus, polio, hepatitis A, bovine viral diarrhea, and Japanese encephalitis, alongside HCV.
5) Does the patent require a specific route of administration?
No route is specified in the provided claim text; infringement is triggered by administering an effective amount of the claimed compound for the listed indications.
References
- US 8,334,270, “(claims provided in prompt text).” United States Patent and Trademark Office.
